Skip to content

Expressie van CCL25 en CCR9 bij inflammatoire darmziekten en primaire scleroserende cholangitis.

Expression of CCL25 and CCR9 in human colon in IBD/PSC patients.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON26243
Enrollment
80
Registered
2011-04-13
Start date
2009-05-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary sclerosing cholangitis inflammatory bowel disease ulcerative colitis Crohn's disease primaire scleroserende cholangitis inflammatoire darmziekten colitis ulcerosa ziekte van Crohn

Interventions

Ileal and colonic biopsies during colonoscopy.

Sponsors

C.IJ. Ponsioen, MD PhD Dept. Gastroenterology and Hepatology Academic Medical Center Amsterdam PO Box 22660 1100 DD Amsterdam The Netherlands c.y.ponsioen@amc.uva.nl
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed PSC patients screened for IBD, ≥18 yr old; 2. a. Newly diagnosed UC patients, ≥18 yr old; 2. b. Infectious enterocolitis patients (bacterial/viral/parasitic), ≥18 yr old; 3. PSC/UC surveillance patients, ≥18 yr old; 4. UC surveillance patients, ≥18 yr old; 5. Controls referred for CRC screening, ≥18 yr old.

Exclusion criteria

Exclusion criteria: 1. Inability to give informed consent; 2. Bleeding diathesis.

Design outcomes

Primary

MeasureTime frame
Expression of CCL25 in human colon.

Secondary

MeasureTime frame
1. Semiquantitative analyses of CCL25 and/or CCR9+ lymphocytes in double stained colonic biopsies between patients and controls; 2. Quantitative analyses of CCL25 mRNA in colon of patients and controls; 3. Quantitative analyses α4β7/CCR9+ T cells in peripheral blood.

Contacts

Public ContactK. Boonstra

PO Box 22660

k.boonstra@amc.uva.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)